Takahari, Daisuke http://orcid.org/0000-0002-2492-6014
Chin, Keisho
Ishizuka, Naoki
Takashima, Atsuo
Minashi, Keiko
Kadowaki, Shigenori
Nishina, Tomohiro
Nakajima, Takako Eguchi
Amagai, Kenji
Machida, Nozomu
Goto, Masahiro
Taku, Keisei
Wakatsuki, Takeru
Shoji, Hirokazu
Hironaka, Shuichi
Boku, Narikazu
Yamaguchi, Kensei
Funding for this research was provided by:
Japanese Foundation for Multidisciplinary Treatment of Cancer (JMFC2015)
Article History
Received: 18 February 2019
Accepted: 8 May 2019
First Online: 17 May 2019
Compliance with ethical standards
:
: Dr. Takahari reports grants and personal fees from Taiho Pharmaceutical Co. and Ono Pharmaceutical Co., and personal fees from Eli Lilly Japan, Bristol-Myers Squibb, Yakult Honsha Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Naoki Ishizuka reports personal fees from Bristol-Myers Squibb, Novartis, and Merck Sharp and Dohme. Dr. Takashima reports grants and personal fees from Taiho Pharmaceutical Co. and Takeda Pharmaceutical Company Ltd, personal fees from Eli Lilly Japan, Ono Pharmaceutical Co., Yakult Honsha Co., Ltd., and Chugai Pharmaceutical Co., Ltd., and grants from Sumitomo Dainippon Pharma and LSK BioPartners. Dr. Minashi reports grants from Merck Sharp and Dohme and Ono Pharmaceutical Co. Dr. Kadowaki reports grants and personal fees from Taiho Pharmaceutical Co. and Eli Lilly, grants from Ono Pharmaceutical Co. and Bristol-Myers Squibb, and personal fees from Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer, and Merck. Dr. Nishina reports grants and personal fees from Taiho Pharmaceutical Co., grants and personal fees from Eli Lilly Japan, Ono Pharmaceutical Co., Bristol-Myers Squibb, Yakult Honsha Co., Ltd., and Chugai Pharmaceutical Co., Ltd., and grants from Daiichi Sankyo, Dainippon Sumitomo Pharma, Boehringer Ingelheim, and Merck Sharp and Dohme. Dr. Nakajima reports grants and personal fees from Taiho Pharmaceutical Co., Ono Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Merck, Merck Sharp and Dohme, and Takeda Pharmaceutical Company Ltd, and personal fees from Eli Lilly Japan, Bristol-Myers Squibb, Yakult Honsha Co., Ltd., Bayer, Sanofi, Sawai Pharmaceutical Company, Limited, Mochida Pharmaceutical Company, Ltd, Kyowa Hakko-Kirin, Dainippon Sumitomo Pharma, Maruho Co. Ltd., Daiichi Sankyo, Eisai Co., Ltd, and AstraZeneca. Dr. Amagai reports grants and personal fees from Taiho Pharmaceutical Co., grants from Merck Sharp and Dohme, and personal fees from Eli Lilly Japan, Bristol-Myers Squibb, Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, and Hisamitsu Pharmaceutical Co., Inc. Dr. Machida reports grants and personal fees from Taiho Pharmaceutical Co., personal fees from Eli Lilly Japan, Ono Pharmaceutical Co., Bristol-Myers Squibb, Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Nippon Kayaku, Daiichi Sankyo, Merck Sharp and Dohme. Dr. Goto reports grants, personal fees and non-financial support from Taiho Pharmaceutical Co., Yakult, Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Takeda Pharmaceutical Company Ltd, Kyowa Hakko Kirin, Novartis, Bayer, and Mochida Pharmaceutical Company, Ltd. Dr. Wakatsuki reports personal fees from Taiho Pharmaceutical Co., Eli Lilly Japan, Bayer, and Chugai Pharmaceutical Co., Ltd. Dr. Hironaka reports personal fees from Taiho Pharmaceutical Co., Eli Lilly Japan, Ono Pharmaceutical Co., Bristol-Myers Squibb, Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Daiichi-Sankyo. Dr. Boku reports grants from Taiho Pharmaceutical Co., Ono Pharmaceutical Co. and Bristol-Myers Squibb, and personal fees from Taiho, Ono Pharmaceutical Co., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., and Eli Lilly. Dr. Yamaguchi reports grants and personal fees from Taiho Pharmaceutical Co., Eli Lilly Japan, Ono Pharmaceutical Co., Bristol-Myers Squibb, Yakult Honsha Co., Ltd., and Chugai Pharmaceutical Co., Ltd., and personal fees from Takeda Pharmaceutical Company Ltd, Bayer, Daiichi-Sankyo, Sanofi, Dainippon-Sumitomo Pharma, Merck Sharp and Dohme, and Gilead Sciences, Inc. All remaining authors have declared no conflicts of interest.
: All procedures followed were in accordance with the ethical standards of the institutional and national committees governing human experimentation and in compliance with the Helsinki Declaration of 1964 and later versions.
: Informed consent or an appropriate substitute was obtained from all patients prior to their inclusion in the study.
Free to read: This content has been made available to all.